Adicet Bio to Participate in the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference
April 15 2021 - 7:00AM
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer and other diseases, today announced that Chen Schor,
President and Chief Executive Officer, will be participating in a
panel discussion at the Canaccord Genuity 2021 Horizons in Oncology
Virtual Conference.
Details of the event are as follows: |
Panel: |
Gamma Delta
CART-Cells, and “Squeezed” T-cells |
Date: |
Thursday, April 15, 2021 |
Time: |
1:00 – 1:55 PM ET |
Format: |
Panel moderated by John Newman, Ph.D., Managing Director,
Biotechnology Analyst |
About Adicet Bio, Inc.Adicet Bio, Inc. is a
biotechnology company discovering and developing allogeneic gamma
delta T cell therapies for cancer and other diseases. Adicet is
advancing a pipeline of "off-the-shelf" gamma delta T cells,
engineered with chimeric antigen receptors and T cell receptor-like
antibodies to enhance selective tumor targeting, facilitate innate
and adaptive anti-tumor immune response, and improve persistence
for durable activity in patients. For more information, please
visit our website at http://www.adicetbio.com.
Adicet Bio., Inc.Investor and Media
ContactsAnne Bowdidgeabowdidge@adicetbio.com
Janhavi MohiteStern Investor Relations,
Inc.212-362-1200janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Apr 2023 to Apr 2024